AUS
NZ
UK
CA
USA
IND
Healthcare
ASX Biotech Companies Focused on Early Cancer Detection
January 21, 2025 11:00 AM AEDT| By Team Kalkine MediaPioneering Advances in Cancer Detection by ASX-Listed Biotechs
Orthocell Ltd. (ASX:OCC) Secures A$3.18 Million R&D Refund and Strengthens Global Market Position
January 20, 2025 01:43 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,Ltd. (,ASX:OCC,) receives,a A,$3.18 million R&D tax refund, boosting its cash reserves to A$33 million.,The company is preparing for a US market entry with its innovative medical devices.,A strategic global expansion is underway,...
EBR's prospects for its US heart lead improve as the wireless device receives approval for expedited reimbursement.
January 20, 2025 11:00 AM AEDT| By Team Kalkine MediaEBR's prospects for its US heart lead improve as the wireless device receives approval for expedited reimbursement.
Optiscan (ASX:OIL) Initiates GI Study in Germany Using Its Initial Imaging Prototype
January 19, 2025 11:00 AM AEDT| By Team Kalkine MediaOptiscan Advances GI Imaging Technology with New Pre-Clinical Study
Is Little Green Pharma (ASX:LGP) Making Prudent Use of Debt?
January 18, 2025 01:32 PM AEDT| By Team Kalkine MediaIs Little Green Pharma (ASX:LGP) Making Prudent Use of Debt?
Lung Imaging Company Cyclopharm (ASX:CYC) Finds Success in the US Market
January 18, 2025 11:00 AM AEDT| By Team Kalkine MediaCyclopharm's Strategic Expansion in the US Healthcare Market
ASX Quarterly Health Summary: EZZ Scores Big, ReNerve's Initial Post-IPO Report
January 18, 2025 11:00 AM AEDT| By Team Kalkine MediaEZZ Life Science and Microba Report Strong Q2 FY25 Growth
How Will OPT-302 Transform the Future of Eye Disease Treatment?
January 18, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Opthea's lead drug, OPT-302, shows significant promise as a new treatment for challenging eye diseases, such as wet AMD and DME.,If Phase III trials yield positive results, OPT-302 could open a large market opportunity, with peak sales by...
Australian High-Growth Tech Stocks Highlighting Infomedia and Two Additional Companies
January 17, 2025 04:30 PM AEDT| By Team Kalkine MediaAustralian High-Growth Tech Stocks Highlighting Infomedia and Two Additional Companies
Telix Pharmaceuticals (ASX:TLX) Gains After EU Approval for Illuccix in Prostate Cancer Treatment
January 17, 2025 12:37 PM AEDT| By Team Kalkine MediaHighlights,Telix,Pharmaceuticals (,ASX:TLX,) shares jump following European approval.,Illuccix,, the prostate cancer diagnostic agent, gets the green light.,The,stock,has risen by over 140% in the past year.,Telix Pharmaceuticals (ASX:TLX), a Melbour...
ResMed Gains Limelight as Goldman Sachs Sets Bullish Target
January 17, 2025 11:39 AM AEDT| By Team Kalkine MediaHighlights,Strong Performance:,ResMed shares have surged 44% in the past 12 months, showing robust investor confidence in the sleep disorder treatment company.,Analyst Endorsement:,Goldman Sachs has initiated coverage with a,buy,rating and a price ta...
Telix Pharmaceuticals Secures European Authorisation for Prostate Cancer Imaging Agent Illuccix®
January 17, 2025 11:31 AM AEDT| By Team Kalkine MediaHighlights,European Approval for Illuccix®:,Telix Pharmaceuticals received a positive decision on its Marketing Authorization Application (MAA) for Illuccix® across 18 European Economic Area (EEA) member states.,Breakthrough in Prostate Cancer Imagin...
Immuron Reports Strong Sales Growth for Travelan® Across Global Markets
January 17, 2025 11:30 AM AEDT| By Team Kalkine MediaHighlights,Global Sales Surge:,Travelan® global sales reached AUD $2.5 million in the December 2024 Quarter, up 70% from the prior quarter and 249% compared to the same period in 2023.,Australian Market Leads Growth:,Australian sales increased 90% qu...
Telix maintains steady growth, while Pro Medicus secures another contract.
January 17, 2025 11:00 AM AEDT| By Team Kalkine MediaTelix maintains steady growth, while Pro Medicus secures another contract.
Phase III Trials: A Critical Moment for These ASX Health Stocks
January 17, 2025 11:00 AM AEDT| By Team Kalkine MediaMajor ASX Biotechs Make Significant Advances in Phase III Trials
How Is Singular Health Group Transforming Medical Imaging Efficiency?
January 17, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Singular Health Group (ASX:SHG) completes Phase 1 of its MOU with Provider Network Solutions, showcasing technical proof of concept.,The company’s proprietary 3Dicom Gateway and Medical File Transfer Protocol reduce medical image processi...
Will Recce Pharmaceuticals' R327G Gel Redefine Infection Treatment?
January 17, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Second phase trial completed with no serious adverse events reported,R327G gel developed for bacterial skin and skin structure infections,Third phase clinical studies planned in the United States, Australia, and Indonesia,Recce Pharmaceuti...
Dimerix Launches Key Paediatric Study in Groundbreaking Phase 3 Clinical Trial
January 16, 2025 08:57 PM AEDT| By Team Kalkine MediaHighlights,Recruitment begins for the first paediatric patient in a pivotal kidney disease trial.,19 specialist sites across multiple countries involved in the paediatric study plan.,Interim data anticipated in August; full recruitment expected by la...
Pro Medicus Signs $33M Deal with University of Kentucky
January 16, 2025 05:19 PM AEDT| By Team Kalkine MediaHighlights,Pro Medicus (ASX:PME) secures a long-term contract valued at $33 million.,Visage 7 Enterprise Imaging Platform to be implemented at University of Kentucky.,Company’s North American market expansion continues with strategic partnerships.,Me...
Pro Medicus (ASX:PME) Secures $33 Million Deal to Modernize Imaging Systems at the University of Kentucky
January 16, 2025 05:06 PM AEDT| By Team Kalkine MediaHighlights,Pro Medicus (ASX:PME) signs a significant $33 million contract with the University of Kentucky.,Visage 7 cloud platform to replace outdated imaging systems across the university.,The 9-year agreement accelerates Pro Medicus’ North American...
Advertise your brand on Kalkine Media